Locate Bio Ltd raises £9.2m venture capital
Locate Bio said it will use the fresh money to finance a clinical study of LDGraft, a bone graft substitute containing a sustained-release...
Bayer's Ask Bio unit starts Phase II heart failure gene therapy
The Phase II trial called GenePHIT is the largest adaptive, double-blind, placebo-controlled, randomised, multicentre trial ever to evaluate the...
Danish 21st.BIO A/S opens multipurpose production plant
Today, EU Executive Vice-President Margrete Vestager launched a multi-purpose pilot production facility in Copenhagen, with which 21st.BIO A/S aims...
Jazz Pharmaceuticals licences KRAS blocker from Redx Pharma
Under the term of the agreement, Redx Pharma plc (Alderley Park, UK) is to receive US$10m upfront and up to US$870m in milestone payments. Redx is...
Roche opens €90m gene therapy development centre
Roche sees the €90m investment as a harbinger of the German government's "National Strategy for Gene and Cell Therapies", which has been...
Pierre Fabre SAS in US$31m licence deal with Kinnate Biopharma Inc
With the US$31m agreement Pierre Fabre licences the global rights to exarafenib and other pan-RAF program assets from Kinnate...
Bioplastics production capacity to quadruple by 2028
Global production capacity for bioplastics will almost quadruple within the next five years, according to estimates of the Nova Institute on behalf...